Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results